Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

461
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
461
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.2K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

623
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
623
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

301
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
301
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

392
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
392
Drug Therapy01:28

Drug Therapy

133
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
133

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An Unsupervised Approach for Artifact Severity Scoring in Multi-Contrast MR Images.

Proceedings of machine learning research·2026
Same author

Clinical Outcomes of Colorectal Endoscopic Full-Thickness Resection Using the Full-Thickness Resection Device: A Multicenter Study.

DEN open·2026
Same author

Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes.

Annals of neurology·2026
Same author

Association of epiretinal membranes with disability in people with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Availability of Folic Acid Fortified Corn Masa Products in Selected Areas in the United States.

Birth defects research·2026
Same author

Metabolomic Signatures of Brain Atrophy and Ibudilast Response in Progressive Multiple Sclerosis.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: Nov 4, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.5K

Early Aggressive Treatment Approaches for Multiple Sclerosis.

Alexandra Simpson1, Ellen M Mowry1, Scott D Newsome1,2

  • 1Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD USA.

Current Treatment Options in Neurology
|May 24, 2021
PubMed
Summary

High-efficacy disease-modifying therapies (DMTs) offer improved outcomes for multiple sclerosis (MS). Emerging data suggest early aggressive treatment may be more beneficial than traditional escalation for managing MS.

Keywords:
Clinical trialsDisease-modifying therapyHigh-efficacy therapiesMultiple sclerosisRelapsing-remitting multiple sclerosis

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.0K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

4.9K

Related Experiment Videos

Last Updated: Nov 4, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.5K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.0K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

4.9K

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system.
  • Disease-modifying therapies (DMTs) are crucial for managing MS, with a growing number of high-efficacy options available.

Purpose of the Study:

  • To comprehensively review current high-efficacy DMTs for relapsing and progressive MS.
  • To analyze treatment considerations for pediatric and pregnant populations.
  • To compare escalation versus early aggressive treatment paradigms for MS.

Main Methods:

  • Review of clinical trials and observational studies on approved and emerging MS DMTs.
  • Analysis of treatment efficacy and safety profiles.
  • Examination of treatment strategies and ongoing comparative trials.

Main Results:

  • High-efficacy DMTs including natalizumab and anti-CD20 therapies show superior efficacy compared to older treatments.
  • Alemtuzumab and mitoxantrone demonstrate efficacy but have significant side effects.
  • Emerging therapies and autologous hematopoietic stem cell transplantation are under investigation for early aggressive MS treatment.

Conclusions:

  • The shift towards an early aggressive treatment approach for MS is driven by the potential long-term benefits of high-efficacy DMTs.
  • Ongoing trials (TREAT-MS, DELIVER-MS) will directly compare early aggressive versus escalation strategies in MS management.